RegeneRx Biopharmaceuticals, Inc. (OTC Bulletin Board: RGRX) ("the Company" or "RegeneRx") announced today that the Company has been notified that two cardiac-related patents will be allowed in Australia and Mexico.
The Australian patent is for the treatment or prevention of damage due to heart failure and will expire in July, 2026.
The Mexican patent is for the treatment or prevention of damage caused by increased blood flow in the myocardium, commonly called reperfusion injury. It will expire in January, 2026.
RegeneRx has similar patents pending in numerous other countries, including in the U.S., Asia and Europe.